Skip to Content
Merck
  • EpCAM-Mediated Cellular Plasticity Promotes Radiation Resistance and Metastasis in Breast Cancer.

EpCAM-Mediated Cellular Plasticity Promotes Radiation Resistance and Metastasis in Breast Cancer.

Frontiers in cell and developmental biology (2021-01-26)
Arijit Mal, Amirali B Bukhari, Ram K Singh, Aastha Kapoor, Amlan Barai, Ishan Deshpande, Tabassum Wadasadawala, Pritha Ray, Shamik Sen, Abhijit De
ABSTRACT

Substantial number of breast cancer (BC) patients undergoing radiation therapy (RT) develop local recurrence over time. During RT therapy, cells can gradually acquire resistance implying adaptive radioresistance. Here we probe the mechanisms underlying this acquired resistance by first establishing radioresistant lines using ZR-75-1 and MCF-7 BC cells through repeated exposure to sub-lethal fractionated dose of 2Gy up to 15 fractions. Radioresistance was found to be associated with increased cancer stem cells (CSCs), and elevated EpCAM expression in the cell population. A retrospective analysis of TCGA dataset indicated positive correlation of high EpCAM expression with poor response to RT. Intriguingly, elevated EpCAM expression in the radioresistant CSCs raise the bigger question of how this biomarker expression contributes during radiation treatment in BC. Thereafter, we establish EpCAM overexpressing ZR-75-1 cells (ZR-75-1EpCAM), which conferred radioresistance, increased stemness through enhanced AKT activation and induced a hybrid epithelial/mesenchymal phenotype with enhanced contractility and invasiveness. In line with these observations, orthotopic implantation of ZR-75-1EpCAM cells exhibited faster growth, lesser sensitivity to radiation therapy and increased lung metastasis than baseline ZR-75-1 cells in mice. In summary, this study shows that similar to radioresistant BC cells, EpCAM overexpressing cells show high degree of plasticity and heterogeneity which ultimately induces radioresistant and metastatic behavior of cancer cells, thus aggravating the disease condition.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-CD24-FITC antibody produced in mouse, clone SN3, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-CD44-APC antibody produced in mouse, clone MEM-263, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Collagen, Type I solution from rat tail, BioReagent, suitable for cell culture, sterile-filtered
Sigma-Aldrich
hBFGF, FGF-Basic, recombinant, expressed in E. coli, suitable for cell culture
Sigma-Aldrich
Puromycin dihydrochloride from Streptomyces alboniger, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Doxorubicin hydrochloride, 98.0-102.0% (HPLC)
Sigma-Aldrich
(±)-Verapamil hydrochloride, ≥99% (titration), powder
Sigma-Aldrich
hEGF, EGF, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
Sigma-Aldrich
Gemcitabine hydrochloride, ≥98% (HPLC)
Sigma-Aldrich
Anti-AKT1 antibody, Rabbit monoclonal, recombinant, expressed in HEK 293 cells, clone RM252, purified immunoglobulin
Sigma-Aldrich
AldeRed® ALDH Detection Assay
SAFC
Insulin, Human Recombinant, dry powder, for research or for further manufacturing use
Sigma-Aldrich
Monoclonal Anti-Vimentin antibody produced in mouse, clone V9, ascites fluid
Sigma-Aldrich
Pluronic® F-127, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Crystal Violet, certified by the Biological Stain Commission
Supelco
Cisplatin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Anti-Phospho-akt (ser473) antibody, Rabbit monoclonal, recombinant, expressed in HEK 293 cells, clone RM251, purified immunoglobulin